EntityQ161515· pop 12· linked from 31 articlestetraxetanSign in to savechemical compoundResearch1,554 papersFDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.Drugs of today (Barcelona, Spain : 1998) · 2023Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.Molecular diagnosis & therapy · 2022Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.Expert review of anticancer therapy · 2022(177)Lu-Vipivotide Tetraxetan ((177)Lu-PSMA-617, Pluvicto) Therapy.Journal of nuclear medicine technology · 2022via PubMedConnectionscalciumEntitygadoliniumEntityCategoriesCarboxylic acidsChelating agentsChembox having GHS dataChemical articles with multiple compound IDsDOTA (chelator) derivativesECHA InfoCard ID from WikidataMacrocyclesMultiple chemicals in an infobox that need indexingOctadentate ligandsSubstances discovered in the 1970s